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Enteroaggregative Escherichia coli (EAEC) are quite heterogeneous category of an emerging enteric pathogen associated with cases
of acute or persistent diarrhea worldwide in children and adults, and over the past decade has received increasing attention as
a cause of watery diarrhea, which is often persistent. EAEC infection is an important cause of diarrhea in outbreak and nonoutbreak settings in developing and developed countries. Recently, EAEC has been implicated in the development of irritable
bowel syndrome, but this remains to be confirmed. EAEC is defined as a diarrheal pathogen based on its characteristic aggregative
adherence (AA) to HEp-2 cells in culture and its biofilm formation on the intestinal mucosa with a “stacked-brick” adherence
phenotype, which is related to the presence of a 60 MDa plasmid (pAA). At the molecular level, strains demonstrating the
aggregative phenotype are quite heterogeneous; several virulence factors are detected by polymerase chain reaction; however, none
exhibited 100% specificity. Although several studies have identified specific virulence factor(s) unique to EAEC, the mechanism by
which EAEC exerts its pathogenesis is, thus, far unknown. The present review updates the current knowledge on the epidemiology,
chronic complications, detection, virulence factors, and treatment of EAEC, an emerging enteric food borne pathogen.

1. Introduction
Diarrheagenic Escherichia coli (E. coli) are the most common bacterial pathogens implicated in diarrhea worldwide. Diarrheagenic pathotypes recognized to date include
enterotoxigenic E. coli (ETEC), which are characterized by
producing heat-labile or heat-stable or both enterotoxins,
enterohaemorrhagic E. coli (EHEC), which are characterized
by attaching-and eﬀacing-(A/E) lesions and shiga-like toxin
or verotoxins, enteropathogenic E. coli (EPEC), which elicit
characteristic attaching and eﬀacing lesions on the intestinal
mucosa, enteroinvasive E. coli (EIEC), which has the ability to
invade epithelial cells similar to Shigella and is characterized
by the presence of a large invasiveness plasmid, diﬀusely
adherent E. coli (DAEC) demonstrates pattern of diﬀuse
adherence, and enteroaggregative E. coli (EAEC), which
demonstrate a characteristic “stacked-brick” aggregative
adherence when cultured with HEp-2 cells [1, 2]. Other
diarrheagenic E. coli pathotypes have been proposed, such

as cell detaching E. coli (CDEC). However, their significance
remains uncertain [3]. EAEC is the most recently identified
diarrheagenic E. coli. EAEC is increasingly recognized as an
emerging enteric pathogen and cause of persistent diarrhea
and malnutrition in children and HIV-infected persons
living in developed countries. It is the second most common
cause of traveler’s diarrhea, and is a common cause of
acute diarrheal illness in children and adults presenting to
emergency departments and inpatient units in the USA [4].
Finally, the USA National Institutes of Health has categorized
EAEC as a category B potential bioterrorism agent [5, 6]. In
the next section, we concisely review current knowledge on
EAEC with a focus on epidemiology, chronic complications,
detection, virulence factors, and treatment of EAEC.

2. Epidemiology
Recently, on the basis of meta-analysis by Huang et al. it
was showed that EAEC is a cause of acute diarrheal illness
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among children residing in both developing and developed
regions, adults and persons with HIV infection residing in
developing regions, and travelers to developing regions in
both developing and industrialized regions, showing that
EAEC strains are relatively heterogeneous, and limited numbers of studies were available that examined the independent
roles of the many putative EAEC virulence genes in acute
diarrheal illness [7]. A growing number of studies have
supported the association of EAEC with persistent diarrhea
in developing countries [8, 9]. A study from Brazil identified
EAEC infection as the most common cause of diarrhea
in small children, and was found to be more frequently
associated with diarrhea in children less than 2 years of
age [10]. The increasing number of such reports and the
rising proportion of diarrheal cases in which EAEC are
implicated suggest that EAEC are important emerging agents
of pediatric diarrhea. Other European studies in children
also indicate that EAEC may be a leading cause of diarrheal
disease in developed countries [11, 12]. The involvement of
EAEC with outbreaks of acute diarrhea aﬀecting newborns
and children were reported in industrialized countries [13].
In a Serbian neonatal ward an outbreak of EAEC diarrhea
was described where 19 babies were aﬀected and 3 developed
weight loss and pyrexia [14]. Several other outbreaks both in
children and in adults have been described in the UK [15],
and France [16].
EAEC is the second most common bacterial pathogen
isolated in US adult traveler’s to developing countries and
deployed US military personnel [17, 18]. In a study of adult
US traveler’s to Mexico that evaluated the serologic response
to the EAEC antiaggregative protein dispersin, 48% of
traveler’s developed increases in antibody response over time;
the majority of patients, though, remained asymptomatic
[19]. EAEC have been described in large case series in
Europe, UK, Switzerland, and Japan in cohort studies of
children, adults, HIV-infected persons, and international
travelers to developing regions who were associated with
acute diarrheal illness [11, 20]. Recent studies have identified
EAEC in HIV patients with persistent diarrhea [4, 21].
A study of Mexican tabletop sauces identified 44% of
sauces from Guadalajara, Mexico, to contain viable EAEC,
compared to 0% of sauces in restaurants in Houston, Texas
[22]. In Italy, two consecutive EAEC outbreaks aﬀecting
24 individuals were linked to contaminated unpasteurized
cheese [23]. In the largest reported outbreak so far, 2697
(40.6%) Japanese children who consumed infected school
lunches had severe diarrhea and EAEC was found in 10% of
cases [24]. Food is also a vehicle of transmission of EAEC
infection and interestingly, EAEC was more likely to be
isolated from food than other bacterial pathogens, including
ETEC [25].

3. Clinical Manifestations and Chronic
Complications
Although not all EAEC infections result in symptomatic
illness, the most commonly reported symptoms are watery
diarrhea with or without blood and mucus, abdominal
pain, nausea, vomiting, and low-grade fever [22]. EAEC can
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cause both an acute and a chronic (>14 days) diarrheal
illness. Electron microscopy of infected small and largeintestinal mucosa, from children between 3 and 190 months,
cultured with several diﬀerent EAEC strains, reveals bacteria
in a thick mucus layer above the intact enterocyte brush
border [26, 27]. In the colon, EAEC elicits inflammatory
mediators and produces cytotoxic eﬀects such as microvillus vesiculation, enlarged crypt openings, and increased
epithelial cell extrusion [28]. Numerous putative virulence
factors, a yersiniabactin system, a complex carbohydratespecific lectin [29], enterotoxins and cytotoxins have been
identified. The gnotobiotic piglet model could be useful
in studying diarrheagenicity and ultrastructural damage
caused by EAEC where germ-free piglets infected with EAEC
showed hyperaemia and swelling of the villi of the small
intestine. In vitro organ culture of human colonic biopsies
probably provides the closest parallel to human infection
and has provided valuable insights to pathogenicity [30].
Malnourished hosts, especially children living in developing
countries, may be unable to repair mucosal damage, and
thus may become prone to persistent or chronic diarrhea
[22]. Perhaps even more significant than the association
of EAEC with persistent diarrhea are the data from Brazil
[31] that link EAEC with growth retardation in infants. The
isolation of EAEC from the stools of infants was associated
with a low z-score for height and/or weight irrespective of the
presence of diarrheal symptoms. Undoubtedly diarrhea is the
commonest cause impairing the growth of a large population
of children in India [32].
Several studies have suggested that patients infected
with EAEC manifest intestinal inflammation, in which the
presence of fecal lactoferrin and proinflammatory cytokines,
notably interleukin (IL)-8, is observed [33]. It is observed
that even asymptomatic carriage of EAEC strains can result
in evidence of low-level enteritis [31]. The myriad variations
of clinical symptoms of EAEC infection are due to factors
such as host genetic susceptibility, host immune response,
heterogeneity of virulence among EAEC strains, and the
amount of bacteria ingested by the infected host [22]. EAEC
has been associated with chronic diarrhea and malnutrition
in children of developing countries and individuals with
HIV infection [18]. In a study in Poland, acute episode of
bacterial diarrhea by EAEC can result in the development of
postinfectious irritable bowel syndrome (IBS) [34]. However,
the pathogenic role of EAEC, if any, in the development of
IBS has not yet been elucidated.

4. Identification and Diagnosis
The identification of EAEC depends on the characteristic
“stacked-brick” aggregative adherence when cultured in
static Luria broth at 37◦ C and incubated for 3 hours in HEp2 cells [1]. Majority of the HEp-2 positive strains were also
positive for the antiaggregation protein transporter gene by
PCR [35]. However, in another study it was found that 10%
of the EAEC strains verified by HEp-2 assay were negative
in the PCR assay clearly provided an evidence to show that
it is diﬃcult to provide a genotypic definition for EAEC
and design specific molecular biological assays for detection
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[36, 37]. The HEp-2 cell adherence assay is currently
performed only in research settings, and is labor intensive.
A clump formation test has also been described to be useful
in the identification of EAEC [38]. Several attempts have
been made to develop a molecular biological assay for the
identification of EAEC. A cryptic DNA fragment sequence
known as “CVD432,” or aggregative adherence (AA), from
the pAA has been used as an EAEC molecular marker in
epidemiological studies and comprises the locus att that
encodes an ABC transporter system [39, 40]. A transcription
activator known as “AggR,” the gene of which lies on pAAs,
has been described as the major EAEC virulence regulator for
diverse virulence genes [41].
Recently, some epidemiological studies have suggested
that CVD432-positive strains, which are predicted to carry
the AggR regulon, are the true EAEC pathogens termed
“typical EAEC” [37, 42]. However, AA probe-negative strains
share virulence factors with AA probe positive isolates, which
clearly indicate that additional factors are involved in the
AA phenotype in these EAEC strains [43]. The problems
in identification of EAEC have been clearly highlighted very
recently where the authors set up a multiplex PCR targeting
three diﬀerent genes: (i) the antiaggregation Aap transporter
gene, (ii) the EAST gene, and (iii) a chromosomal gene
present in the pheU pathogenicity island designated aggRactivated island [37]. In this study, 143 EAEC strains were
analyzed and 128 (90%) were positive for the antiaggregation
protein (Aap) transporter gene [37]. However, 10% of the
strains verified by HEp-2 assay were negative in the PCR
assay. This makes it diﬃcult to provide a genotypic definition
for EAEC and to design specific molecular biological assays
for the detection of this pathotype.
The CVD432+ strains were associated with persistent
diarrhea in children younger than 12 months of age. However, in children older than 12 months of age, the genotype
associated with protracted diarrhea was CVD432+ EAST1+
statistically associated only with acute diarrhea in both age
groups [44]. The loss of the positive correlation of EAST1+
strains with diarrhea may be associated, in part, with the
immature stages of intestinal development [44]. Recently, a
study demonstrated that EAEC bacterial DNA can be recovered from dry fecal occult blood detection cards by PCR.
This may be of use when collection and transportation of
fecal samples from the field to the laboratory is diﬃcult [45].
A problem with using DNA probes for EAEC demonstrates
heterogeneity and no single study has been able to demonstrate a 100% correlation with the HEp-2 cell assay [46].
Biofilm assay is also useful in screening when a large
number of strains are examined in clinical and epidemiologic
studies. All EAEC strains in this study demonstrated an
OD570 > 0.2 in the assay, and the incidence of EAEC among
the strains with an OD570 > 0.2 was 89.2% [38, 47, 48].
Furthermore, the test may be available without a spectrophotometer, since a biofilm demonstrating an OD570 > 0.2 is clearly visible. In addition, this assay may contribute to demonstrating of the true incidence of EAEC with and without
AggR among clinically isolated E. coli strains. Of the 28
PCR-positive (AggR and EAST) strains screened for biofilm,
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25 (89.2%) demonstrated positive results by microtiter plate
method.
Recently, sera from children (control group) living in
an endemic area show no antibody response to Pet but
that those from children with diarrhea caused by EAEC
showed high titers of antibody against this toxin [49].
In addition, rabbit antiPet sera recognized 50% of the
EAEC strains recovered from stools after culture supernatant
concentration by immunoblotting [49]. The emergence of
EAEC infection in Brazil [50] and the detection complexity
of Pet expressing EAEC isolates led to the development of
a methodology for Pet detection directly from supernatants
of bacterial isolates using a slot blot immunoassay [51].
Other proposed diagnostic tests include an enzyme-linked
immunosorbent assay (ELISA) for quantitative detection of
secretory immunoglobulin A to EAEC [52] and cytokine
response patterns to enteropathogens in which a specific
pattern may become a distinguishing pathogen signature
[33]. More studies and better diagnostic tools are needed to
allow for a better understanding of the true epidemiology of
EAEC in children.
Serotyping of EAEC is a problem due to their aggregative
phenotype, many of the strains auto-agglutinate and is often
described in the literature as nontypable or as O-rough.
EAEC from German children demonstrated 14 typable
isolates and all belonged to diﬀerent serotypes [53]. In
another study in UK, 97 EAEC strains were serotyped to 40
diﬀerent O-types. In one of the studies, 93 out of 143 EAEC
strains could be serotyped and belonged to as many as 47
diﬀerent serotypes [37]. Serotyping is really no longer useful
in the diagnosis of diarrheagenic E. coli infections.

5. Pathogenesis
The pathogenesis of EAEC is really complex as strains are
relatively heterogeneous. The best-studied virulence factor is
AggR, the master regulator of EAEC virulence, which controls expression of adherence factors, a dispersin protein, and
a large cluster of genes encoded on the EAEC chromosome
[41]. EAEC pathogenesis involves three stages: (1) adherence
to the intestinal mucosa by aggregative adherence fimbriae
(AAF) and adherence factors, (2) increased production of
mucus that encrusts EAEC on the surface of enterocytes;
and (3) release of toxins and elicitation of an inflammatory
response, mucosal toxicity, and intestinal secretion [28, 41].
AggR regulates the expression of a secreted low-molecular
weight protein known as dispersin (aap) which has been
identified in 80% of EAEC isolates from one laboratory [54].
Dispersin is responsible for mediating an antiaggregation
phenotype by inducing changes in the outer membrane
polarization of the bacterial cell, which requires an ABC
transporter system encoded by the att [55]. In a volunteer
challenge study, dispersin has been demonstrated to be
highly immunogenic, suggesting that it is a potential vaccine
candidate [56]. Unlike dispersin, a separate transporter
located in the outer membrane protein (OMP) called TolC,
which is encoded by the AatA and has also been associated
with the secretion of a yet to be characterized factor that
contributes to aggregation [57]. Multidrug resistance eﬄux
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pumps including the AcrAB-TolC system have been reported
to be associated with the colonization and persistence of
bacteria in the host and to have roles in bacterial pathogenicity [58, 59]. One study suggested that strains possessing
CVD432 and EAST-1 virulence markers are most commonly
associated with chronic diarrhea in children [60]; whereas
another study suggested that strains possessing aggR, aap,
and astA (which encodes for EAST-1 protein) are most
commonly associated with acute diarrhea in adults [61].
EAEC adherence to the intestinal mucosa requires fimbrial structures called aggregative adherence factors (AAF)
[62]. Although three fimbriae encoded by the pAA plasmid
are aggA (AAF/I), aafA (AAF/II), and agg-3 (AAF/III), each
EAEC isolate carries only one AAF subtype. aggA is responsible for the aggregative phenotype and human erythrocyte
haemagglutination of EAEC [63]. aafA allows EAEC to
adhere to the intestinal mucosa [64]. agg-3 functions as an
adhesin [65]. Three membrane-associated proteins (MAP),
of 18, 20 and 58 kDa, are believed to play an important role
in EAEC adherence to and haemagglutination of animal cells
[66]. One study has characterized the OMP profiles of EAEC
strains from children with diarrhea from Sao Paulo, Brazil,
and has observed a heterogeneity in OMP profiles [66]. The
binding of EAEC fimbriae to the extracellular matrix proteins
fibronectin, laminin, and type IV collagen is an initial step in
adherence to the intestinal mucosa [67].
Certain strains carry a high molecular weight plasmid
associated with the aggregative adherence on which a
number of virulence genes are located [68]. Furthermore,
a serine protease involved in the colonization process (Pic)
is encoded by the chromosome from strain 042 [30, 69].
Other virulence factors that are believed to be associated
with EAEC are 18 and 30 kDa outer membrane adhesins
[70, 71]. Recently, two de novo OMP of sizes 41 kDa
and 48 kDa demonstrated significant cross reactivity with
known adhesins were observed in EAEC at pH 4.0 [72,
73]. However, some EAEC strains with “stacked-brick”
aggregative adherence lack AAF, suggesting the presence of
other adhesion mechanisms. A novel aggregative adhesion
pilin has recently been demonstrated in EAEC strains lacking
known AAF. This novel adhesion pilin is encoded by hdaA,
also regulated by the AggR regulon [74], is distantly related
to the Dr family of adhesins. Undoubtedly, other potential
AAF and adherence factors exist, and need to be explored.
In addition, diﬀerent pathogenicity islands have been
identified within the EAEC group, including Shigella she
pathogenicity island, containing enterotoxin and mucinase
genes [69], and Yersinia high-pathogenicity island, containing the yersiniabactin siderophore gene [75]. pheU
pathogenicity island in the chromosome of EAEC is regulated by AggR [76]. A few EAEC carry the haemolysinpyleonephritis associated pili island associated with extraintestinal E coli and show a cell-detaching-aggregative phenotype on HEp-2 cells [77]. EAEC strains frequently have toxin
genes located on the chromosome, where genes involved in
iron capture, such as irp2 and fyuA, were also found [78].
A pathogenicity island, the locus for proteolysis activity, is
also present in some EAEC [79]. Recently, a novel secretion
system, called type VI secretion (T6S) system (T6SS) present
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on the pheU pathogenicity island with two copies of T6S gene
clusters, called sci-1 and sci-2 has been reported in EAEC
[80]. sciN is a critical gene necessary for T6S-dependent
secretion of the Hcp-like SciD protein and for biofilm
formation [80].
The second stage of EAEC pathogenesis involves adherence to the mucosa characterized by the presence of a
thick, aggregating biofilm [48]. Animal and in vitro culture studies demonstrate that EAEC survives within the
mucus layer, explaining why individuals infected with EAEC,
especially children in developing countries with pre-existent
malnutrition, may develop mucoid stools, malnutrition, and
persistent colonization with prolonged diarrhea. However,
the mucus layer and biofilm possibly do not explain malnutrition in aﬀected children. This is because, for the biofilm to
impair nutrient absorption, it would have to cover most of
the small intestinal mucosa, but there is no evidence that this
actually occurs. It is more likely that inflammatory responses
or altered intestinal microbiota are primarily responsible.
One study has identified biofilm production in 48 of 62
(77%) EAEC strains from Japanese children with diarrhea,
using a quantitative biofilm assay, suggesting that this assay
may be a useful and convenient screening tool for EAEC
[48]. Recently, Pic protease has been reported in intestinal
colonization and growth of EAEC [81]. The production
of biofilm is also regulated by AggR and requires several
genes, including Fis, which codes for a DNA-binding protein
involved in growth regulation, and yafK, which codes for
a 28-kDa protein [82]. EilA, a HilA-like regulator, and air,
encoding the predicted OMP in EAEC chromosome, are
associated with biofilm formation [83]. Recently, a gene
coding for the 32.8-kDa Shf protein has been localized in one
of the three open reading frames between aafC and aatA, and
has also been implicated in biofilm formation [84]. However,
loss of biofilm formation and diﬀuse adherence pattern was
observed in EAEC at pH 4.0 whereas at pH 7.4, typical
aggregative adherence pattern was observed (Figure 1) [72,
73].
The third stage of EAEC pathogenesis involves the
cytotoxic eﬀects by release of toxins and an elicitation of
the inflammatory response, mucosal toxicity, and intestinal
secretion [42]. Both animal and human studies demonstrate
that EAEC toxins are destructive to the tips and sides of
intestinal villi and enterocytes. There are to date, three toxins
described in EAEC; the plasmid encoded toxin (Pet), a
serine protease autotransporter that cleaves alpha III spectrin
within the cytoskeleton of the epithelium, resulting in cell
elongation and exfoliation [85], a heat-stable toxin (EAST1)
encoded by astA gene [44], and Shigella enterotoxin 1
(ShET1), which shares similarities with Shigella enterotoxin.
The major obstacle in identifying the mechanism of
pathogenesis for EAEC is the diversity and to a certain extent
heterogeneity of strains [32, 86]. The heterogeneity of EAEC
provides some explanation for the failure of some studies to
associate these strains with disease and suggests that only a
subset of EAEC strains are pathogenic for humans. EAEC
has been clearly associated with diarrhea in some individuals;
but in many others, EAEC strains appear to cause subclinical
infections or intestinal colonization. These bacteria exert
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regions of a number of other cytokine genes such as TNFα, IL-1β, IL-1ra, IL-4, and IL-6 have been shown to have an
impact on the type of immune response [91].

6. Treatment and Prophylaxis

Figure 1: Aggregative adherence pattern of EAEC. HEp-2 cells
(106 ) were grown to 50%–70% confluency as monolayers in a 6well flat-bottom tissue culture plate. After overnight growth cells
were washed and 2 mL of fresh DMEM media (pH 7.4) was added,
and EAEC grown overnight at 37◦ C (215 rpm) was inoculated
(25 μL) into the plate and incubated at 37◦ C overnight in 5% CO2
atmosphere. Following incubation, the cells were washed, fixed, and
stained with 2.5% Giemsa for 15 minutes. The adherence patterns
were examined under 40-X magnification and photographed at
100-X magnification with digital camera in a light microscope.
Data are a representative experiment from three independently
performed experiments with similar results.

a complex pathogen-host immune interaction where the
host inflammatory response to EAEC infection is dependent
on the host innate immune system and the EAEC strain.
EAEC carrying “virulence” genes are not always associated
with disease; however, virulence factors are associated with
increased levels of fecal cytokines and inflammatory markers,
such as interleukin (IL)-1ra, IL-1β, IL-8, interferon (INF)-γ,
lactoferrin, fecal leukocytes, and occult blood [5, 87]. IL-8 is
an important proinflammatory chemokine involved in EAEC
pathogenesis and is responsible for recruiting neutrophils to
the epithelial mucosa without mucosal injury, and facilitates
intestinal fluid secretion [88].
Clinical manifestations of EAEC diarrhea vary from
individual to individual, depending upon the genetic composition of the host [89]. The presence of an AA genotype at the
−251 position in the IL-8 promoter region homozygous for a
single nucleotide polymorphism (SNP) produces higher levels of fecal IL-8 and more frequently develops symptomatic
EAEC diarrhea than those heterozygous for the gene after
exposure to EAEC [89, 90]. In addition to IL-8, intestinal
epithelial cells infected with EAEC 042, the prototype strain,
upregulate the expression of IL-6, tumor necrosis factor
(TNF)-α, growth-related gene product (GRO)-α, GROγ, intercellular adhesion molecule (ICAM)-1, granulocyte
macrophage colony-stimulating factor (GM-CSF), and IL1α. These cellular responses are primarily mediated by flagellin (fliC), a major bacterial surface protein of EAEC [28],
which causes IL-8 release by binding to Toll-like receptor
5 (TLR5). TLR5 signals through P38 mitogen-activating
protein kinase (MAPK) and nuclear factor-kappa B (NF-κB)
induce transcription of pro-inflammatory cytokines from
monocytic cells. In addition, SNPs in regulatory and codon

As with other self-limiting infections, the decision to use
antibiotic therapy should be done on an individual basis
[90] and the antibiotic selection depends on the local
antimicrobial susceptibility patterns. In most regions of the
world, EAEC strains are susceptible to fluoroquinolones,
azithromycin, rifaximin, amoxycillin/clavulanic acid, and
nalidixic acid [92, 93]. One study suggests that integrons
that include the dfrA5, aadA1a, drA13, and oxa5 cassette
may be responsible for antibiotic resistance in EAEC [94].
The association of EAEC with persistent disease makes
this syndrome less amenable to management with oral
rehydration therapy alone, and thus the development of
preventive strategies, including vaccination, would be a high
priority for areas in which this disease commonly occurs.
Surprisingly, there is only one reported randomized trial
for the eradication of EAEC diarrhea in HIV/AIDS patients,
but none has been done in children or other populations
[95]. Recently, a vaccine trial to prevent ETEC diarrhea using
ETEC heat-labile toxin as an antigen demonstrated that by
preventing ETEC associated diarrhea the rates of infection
due to other enteric pathogens, including EAEC, decreased
[96]. Candidates under investigation as potential critical
antigens include the AAF fimbriae and the dispersin protein
coat, which might be a promising EAEC immunogen.
Additional studies and better diagnostic tools are needed to
allow an understanding of the true epidemiology of EAEC.
Lactoferrin purified from human milk (Sigma-Aldrich
Co., St. Louis, MO), recombinant human lactoferrin (Agennix, Houston, TX), and bovine lactoferrin (Tatua Cooperative Dairy Co., Morrinsville, New Zealand) inhibit the
aggregative adherence “stacked-brick pattern” of EAEC in
tissue cultured cells [97]. Bovine lactoferrin also inhibited
EAEC biofilm formation and increased autoagglutination,
further suggesting that surface adhesins were aﬀected. In
another study, histidine tagged dispersin and the surface
fimbria (AAF-II) showed lactoferrin-induced loss and degradation of AAFII but not of dispersin [97]. A clinical trial
of 298 Japanese children less than 5 years of age showed
that daily consumption of 100 mg of bovine lactoferrincontaining products (Morinaga Milk Industry Co., Tokyo,
Japan) versus placebo for 3 months had no eﬀect on the
incidence of rotavirus gastroenteritis; however, there was a
significant lower frequency and duration of vomiting and
diarrhea in the lactoferrin group (P < .05) [98]. A study
of 140 Peruvian children with acute watery diarrhea and
dehydration showed that adding recombinant human lactoferrin and lysozyme (Ventria Bioscience, Sacramento, CA) to
oral rehydration solution reduced the duration of diarrhea
and relapse after 48 hours (9% vs. 19%) [99]. Lactoferrin
has been demonstrated in vitro to be able to inhibit EAEC
enteroadhesion and biofilm formation; however, it is not
yet clear whether lactoferrin as a nonantibiotic approach is
eﬀective for the treatment and prophylaxis of EAEC [100].
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In addition, IL-8 genotypes may define populations likely to
benefit from therapeutic intervention such as prophylactic
antibiotics and vaccines.

7. Conclusion
In recent years there has been significant progress in our
knowledge of the epidemiology, pathogenesis, detection,
treatment, prevention, and possible chronic complications
of EAEC. EAEC is an increasingly recognized cause of acute
and chronic diarrhea among children, adults, and HIVinfected persons. EAEC has been responsible for diarrhea
in a volunteer study and in numerous outbreaks and casecontrol studies from both the developing and the developed
worlds [77]. The HEp-2 cell adherence assay remains the gold
standard for EAEC identification. One of the major diﬃculties in identifying the mechanism of pathogenesis for EAEC
is the diversity and to certain extent heterogeneity of EAEC
strains. No virulence factor has been identified as common
to all EAEC strains. This pathogen is being underestimated
and underdiagnosed. EAEC pathogenesis is a complex hostpathogen interaction that involves host genetic susceptibility,
heterogeneity of virulence among EAEC strains, and the
amount of bacteria ingested by the infected host. EAEC
infections are usually self-limiting, and should be managed
on an individual basis. Greater recognition of EAEC infection
likely will occur with the development of better diagnostic
tools, which likely will yield identification of epidemiologic
patterns of illness and the development of new treatment
recommendations.
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nuclear factor-kappa B
outer membrane protein
once daily
polymerase chain reaction
plasmid-encoded toxin
protease involved in colonization
reversible ileal-tie in adult rabbit diarrhea
Shigella enterotoxin
single nucleotide polymorphism
human colorectal adenocarcinoma cells
Toll-like receptor
tumor necrosis factor.
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